Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?

Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4S, UK; Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton ON L8L 2X2, Canada; Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA; Stanford University, 300 Pasteur Dr, Stanford, CA 94305, USA; and Assistance Publique-Hôpitaux de Paris, 3 Avenue Victoria, 75004 Paris, France

[1]  Deepak L. Bhatt,et al.  External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry , 2018, European heart journal.

[2]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.

[3]  Khalid Yusoff,et al.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.

[4]  Marc P. Bonaca,et al.  Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. , 2017, Journal of the American College of Cardiology.

[5]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[6]  Deepak L. Bhatt,et al.  Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. , 2017, The Canadian journal of cardiology.

[7]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[8]  K. Mahaffey,et al.  Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease , 2017, The New England journal of medicine.

[9]  Peter Sandercock,et al.  Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[10]  Marc P. Bonaca,et al.  Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. , 2016, JACC. Cardiovascular interventions.

[11]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[12]  S. Johnston,et al.  Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[13]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[14]  Nicholas Moore,et al.  Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction , 2016, European heart journal. Quality of care & clinical outcomes.

[15]  Marc P. Bonaca,et al.  Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. , 2015, European heart journal.

[16]  T. Jernberg,et al.  Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.

[17]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[18]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[19]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[20]  Solid-Timi Investigators.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .

[21]  Jeroen J. Bax,et al.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.

[22]  N. Deshpande,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization , 2013 .

[23]  Deepak L. Bhatt,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.

[24]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[25]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[26]  Giuseppe Ambrosio,et al.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.

[27]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[28]  F. Van de Werf,et al.  Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.

[29]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[30]  Deepak L. Bhatt,et al.  Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). , 2010, The American journal of cardiology.

[31]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[32]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[33]  Deepak L. Bhatt,et al.  Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. , 2009, European heart journal.

[34]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[35]  S. Yusuf,et al.  Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. , 2007, The New England journal of medicine.

[36]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[37]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[38]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[39]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[40]  J. Cook,et al.  Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit , 2005, Annals of Internal Medicine.

[41]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[42]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[43]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[44]  B. Meyers,et al.  The American Association for Thoracic Surgery , 2016 .

[45]  Dylan L. Steen,et al.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014, JAMA.

[46]  B. Gersh,et al.  ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology , 2013 .

[47]  A. Rabinstein.  Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial , 2008 .

[48]  X. Álvarez,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events , 2007 .

[49]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[50]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .